Joint with: Obesity and Adipose Tissue
MASH Pathogenesis and Therapeutic Approaches
Feb 23–26, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Elizabeth K Speliotes, Rebecca A. Taub, and Hannele Yki-Järvinen
In Person
On Demand
×
-
Feb 23–26, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers: Elizabeth K Speliotes, Rebecca A. Taub, and Hannele Yki-Järvinen
Elizabeth K Speliotes
Rebecca A. Taub
Hannele Yki-Järvinen
Available Formats:
Supported by:
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Sunday, February 23, 2025
Fundraising
Booking Function
Registration
4:00–8:00 PM
Van Horne Foyer
Welcome Mixer
6:00–8:00 PM
Van Horne Foyer
Monday, February 24, 2025
Breakfast
7:00–8:00 AM
President's Hall
Welcome and Keynote Session (Joint)
8:00–9:30 AM
Van Horne A/B
* Paul Cohen, Rockefeller University
Session Chair
Session Chair
* Elizabeth K Speliotes, University of Michigan
Session Chair
Session Chair
Jeffrey M. Friedman, Rockefeller University
Obesity Causes and Treatment: The End of the Beginning
Obesity Causes and Treatment: The End of the Beginning
Anna Mae Diehl, Duke University
Morphogens, Metabolism and MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Morphogens, Metabolism and MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Coffee Break
9:30–9:50 AM
Van Horne Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Van Horne A/B
Genetic Insights into Body Fat Distribution and MASLD (Joint)
9:55–11:30 AM
Van Horne A/B
* Lucile Dollet, University of Copenhagen
Session Chair
Session Chair
Elizabeth K Speliotes, University of Michigan
Human Genetic Insights into MASLD
Human Genetic Insights into MASLD
* Ruth J Loos, University of Copenhagen
Genetics of Obesity and Body Fat Distribution
Genetics of Obesity and Body Fat Distribution
Karen L. Mohlke, University of North Carolina at Chapel Hill
Genetics and Genomics of Obesity-Associated Diseases
Genetics and Genomics of Obesity-Associated Diseases
Poster Setup
11:30–1:00 PM
Van Horne C
On Own for Lunch
11:30–2:30 PM
Poster Viewing
1:00–10:00 PM
Van Horne C
Health Equity Forum (Joint)
2:30–4:30 PM
Van Horne A
* Joeva Barrow, Cornell University
Session Chair
Session Chair
* Keren I Hilgendorf, University of Utah
Lean Adipocytes Secrete an Oxylipin That Protects Against Obesity-Accelerated Breast Cancer
Lean Adipocytes Secrete an Oxylipin That Protects Against Obesity-Accelerated Breast Cancer
Lisa Lazarevski, University of Tübingen
Unraveling the Impact of White Adipose Tissue on Breast Cancer Metabolism And Therapy Resistance Using a Breast Cancer-On-Chip Model
Unraveling the Impact of White Adipose Tissue on Breast Cancer Metabolism And Therapy Resistance Using a Breast Cancer-On-Chip Model
Clarissa Strieder-Barboza, Texas Tech University
Single-Nuclei Analysis Reveals Depot- And Disease-Specific Cell Types In Adipose Tissue Of Women With Gestational Diabetes
Single-Nuclei Analysis Reveals Depot- And Disease-Specific Cell Types In Adipose Tissue Of Women With Gestational Diabetes
Jennifer Below, Vanderbilt University Medical Center
Unmasking Early Cardiometabolic Risk In A High Risk Population
Unmasking Early Cardiometabolic Risk In A High Risk Population
Elizabeth C Heintz, Pennington Biomedical Research Center
Deletion of Hepatocyte NRF2 Accelerates MASH Progression Through Similar Mechanisms in Male and Female Mice
Deletion of Hepatocyte NRF2 Accelerates MASH Progression Through Similar Mechanisms in Male and Female Mice
Marijana Vujkovic, Philadelphia VA Medical Center / University of Pennsylvania
Genetic Variants Influence Chronic Liver Disease Progression through Distinct Pathways
Genetic Variants Influence Chronic Liver Disease Progression through Distinct Pathways
Donna Conlon, University of Pennsylvania
The Role of FOG2S657G in Metabolic Dysfunction-Associated Steatohepatitis
The Role of FOG2S657G in Metabolic Dysfunction-Associated Steatohepatitis
Jashdeep Bhattacharjee, University of Southern California
The Role of MALRD1 on MASH Pathogenesis
The Role of MALRD1 on MASH Pathogenesis
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Drivers of MASH
5:00–7:00 PM
Van Horne B
* Sami F Qadri, University of Helsinki
Session Chair
Session Chair
Hannele Yki-Järvinen, University of Helsinki
PNPLA3 Mechanisms and Beyond
PNPLA3 Mechanisms and Beyond
* Xavier Revelo, University of Minnesota
Immune Mechanisms in MASH
Immune Mechanisms in MASH
Orian S Shirihai, David Geffen School of Medicine at UCLA
Mitochondrial Biology and MASH
Mitochondrial Biology and MASH
Harmeet Malhi, Mayo Clinic
Extracellular Vesicles in MASH: Mediators of Injury, Inflammation, and Potential Therapeutic Targets
Extracellular Vesicles in MASH: Mediators of Injury, Inflammation, and Potential Therapeutic Targets
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Poster Session 1
7:30–10:00 PM
Van Horne C
Tuesday, February 25, 2025
Breakfast
7:00–8:00 AM
President's Hall
Cellular Stress, Fibrosis and MASLD
8:00–11:00 AM
Van Horne B
* Russell Goodman, Massachusetts General Hospital
Reductive Stress and Common Pathophysiology of Metabolic Disease
Reductive Stress and Common Pathophysiology of Metabolic Disease
* Natalie J. Torok, Stanford University
Fibrosis in MASLD and Aging
Fibrosis in MASLD and Aging
Jin Ye, UT Southwestern
MASH: The Ferroptotic Diseases
MASH: The Ferroptotic Diseases
Karthickeyan Chella Krishnan, University of Cincinnati
Short Talk: Role of Hepatic Mitochondrial Subpopulations in MASH Progression
Short Talk: Role of Hepatic Mitochondrial Subpopulations in MASH Progression
Erin C Ciske, University of Minnesota
Short Talk: Pyruvate Metabolism Promotes B Cell Activation in Steatohepatitis
Short Talk: Pyruvate Metabolism Promotes B Cell Activation in Steatohepatitis
Yo Han Lee, Ulsan National Institute of Science and Technology
Short Talk: Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1
Short Talk: Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1
Reddemma Sandireddy, Duke-NUS Medical School, National University of Singapore
Short Talk: Linking the Liver and Heart: MASH as a Key Driver of HFpEF in a Dietary Mouse Model of Liver Disease
Short Talk: Linking the Liver and Heart: MASH as a Key Driver of HFpEF in a Dietary Mouse Model of Liver Disease
Coffee Break
9:00–9:20 AM
Van Horne Foyer
Poster Setup
11:00–1:00 PM
Van Horne C
On Own for Lunch
11:00–3:15 PM
Poster Viewing
1:00–10:00 PM
Van Horne C
Career Roundtable (Joint)
1:30–3:00 PM
Van Horne B
Ricardo J. Samms, Eli Lilly and Company
Senior Director
Senior Director
Alexander Pfeifer, University of Bonn
Professor
Professor
Marie Guerraty, University of Pennsylvania
Assistant Professor
Assistant Professor
Henry H. Ruiz, New York Institute of Technology
Assistant Professor
Assistant Professor
Catherine Charneski, Science Translational Medicine
Senior Editor
Senior Editor
Meet the Editors (Joint)
3:15–4:30 PM
Van Horne B
Deniz Senyilmaz Tiebe, EMBO Press
*Session Chair, Senior Scientific Editor
*Session Chair, Senior Scientific Editor
Yevgeniya Nusinovich, AAAS/Science
Senior Editor
Senior Editor
Revati Sumukh Dewal, Nature Metabolism
Associate Editor
Associate Editor
Mari-Carmen Fernández-Agüera, Cell Metabolism, Cell Press
Scientific Editor
Scientific Editor
Rachel Sager, Med, Cell Press
Associate Scientific Editor
Associate Scientific Editor
George Caputa, Nature
Senior Editor
Senior Editor
Tatyana Kuznetsova, Cell Reports Medicine
Senior Scientific Editor
Senior Scientific Editor
Catherine Charneski, Science Translational Medicine
Senior Editor
Senior Editor
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Challenges and Innovations in Preclinical Disease Modeling
5:00–7:00 PM
Van Horne B
* Michele Vacca, University of Bari & Roger Williams Institute of Liver Studies
An Unbiased Ranking of Murine Dietary Models based on their Proximity to Human Metabolic Dysfunction Associated Steatohepatitis
An Unbiased Ranking of Murine Dietary Models based on their Proximity to Human Metabolic Dysfunction Associated Steatohepatitis
* Jacquelyn Maher, University of California, San Francisco
iPSC Modeling of Liver Disease
iPSC Modeling of Liver Disease
Carla Frau, BIH-Charite, MPIMG
Mechanisms controlling liver regeneration during MASH progression
Mechanisms controlling liver regeneration during MASH progression
Francisco Verdeguer, InSphero
Short Talk: Multiparametric Screening of MASH Clinical Candidates In Human Liver Spheroids Predicts Clinical Outcomes And Reveals Potential Novel Combinations For Anti-Steatotic And Anti-Fibrotic Therapies
Short Talk: Multiparametric Screening of MASH Clinical Candidates In Human Liver Spheroids Predicts Clinical Outcomes And Reveals Potential Novel Combinations For Anti-Steatotic And Anti-Fibrotic Therapies
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Poster Session 2
7:30–10:00 PM
Van Horne C
Wednesday, February 26, 2025
Breakfast
7:00–8:00 AM
President's Hall
The Biology of Therapeutics for Obesity and MASLD (Joint)
8:00–11:00 AM
Van Horne A/B
* Matthew Lynes, MaineHealth
Session Chair
Session Chair
* Luca Lotta, Regeneron Pharmaceuticals Inc.
CIEDB, GPR75, INHBE in Obesity and MASLD
CIEDB, GPR75, INHBE in Obesity and MASLD
Rebecca A. Taub, Madrigal Pharmaceuticals
Thyroid Agonist Biology and Human Effects
Thyroid Agonist Biology and Human Effects
Ricardo J. Samms, Eli Lilly and Company
Dual Agonist Biology and Human Effects
Dual Agonist Biology and Human Effects
Jacqueline Beaudry, University of Toronto
Short Talk: Clearance Of Postprandial Lipid Levels Into Adipose Tissue With The Help Of Glucose-Dependent Insulinotropic Peptide
Short Talk: Clearance Of Postprandial Lipid Levels Into Adipose Tissue With The Help Of Glucose-Dependent Insulinotropic Peptide
Carla Hovarth, ETH Zürich
Short Talk: Adipose Tissue as A First Responder: Early Effects of Survodutide on Systemic Insulin Sensitivity
Short Talk: Adipose Tissue as A First Responder: Early Effects of Survodutide on Systemic Insulin Sensitivity
Joanne Hsieh, Gordian Biotechnology
Short Talk: Interrogating The Directionality And Mechanisms Of Genetic Associations As Part Of High-Throughput In Vivo Pooled Screening To Discover Novel Therapies For MASH
Short Talk: Interrogating The Directionality And Mechanisms Of Genetic Associations As Part Of High-Throughput In Vivo Pooled Screening To Discover Novel Therapies For MASH
Prabhu Ponnandy, University of Michigan
Short Talk: CRISPR Whole Genome Knock-Out Screen Identifies Potential New Targets For Treatment of MASLD
Short Talk: CRISPR Whole Genome Knock-Out Screen Identifies Potential New Targets For Treatment of MASLD
Coffee Break
9:00–9:20 AM
Van Horne Foyer
Poster Setup
11:00–1:00 PM
Van Horne C
On Own for Lunch
11:00–2:30 PM
Poster Viewing
1:00–10:00 PM
Van Horne C
Symposia Spotlight: Emerging Mechanisms
2:30–4:30 PM
Van Horne B
John J. Lemasters, Medical University of South Carolina
Remote Presenter: Aldehydes Initiate the Shared Pathogenesis of Metabolic Dysfunction-Associated and Alcohol-Associated Steatohepatitis by Inducing Mitochondrial Depolarization, Mitophagy, and Release of Profibrotic and Proinflammatory Mitochondrial Damage-Associated Molecular Patterns
Remote Presenter: Aldehydes Initiate the Shared Pathogenesis of Metabolic Dysfunction-Associated and Alcohol-Associated Steatohepatitis by Inducing Mitochondrial Depolarization, Mitophagy, and Release of Profibrotic and Proinflammatory Mitochondrial Damage-Associated Molecular Patterns
Eri Wada, Nagoya University
The Role of β2 Adrenergic Receptor in MASH
The Role of β2 Adrenergic Receptor in MASH
* Jesse Rose, University of Iowa
Fibroblast Growth Factor 21 Reverses MASH Through Coordinated Actions on the CNS and liver.
Fibroblast Growth Factor 21 Reverses MASH Through Coordinated Actions on the CNS and liver.
* Wen-Wei Tsai, Sagimet Biosciences
Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study
Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study
Benan Pelin Sermikli, Salk Institute for Biological Studies
Circadian FGF1 Signaling Orchestrates Nocturnal Hepatic Triglyceride Secretion via Non-Canonical IRE1a-XBP1 Pathway Activation
Circadian FGF1 Signaling Orchestrates Nocturnal Hepatic Triglyceride Secretion via Non-Canonical IRE1a-XBP1 Pathway Activation
Rafael Mayoral Monibas, Corcept Therapautics
Metabolomic and Lipidomic Analysis of Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treated with the Selective Glucocorticoid Receptor Modulator Miricorilant
Metabolomic and Lipidomic Analysis of Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treated with the Selective Glucocorticoid Receptor Modulator Miricorilant
Thomas Q de Aguiar Vallim, University of California, Los Angeles
Bile Acids Selectively Drive Fatty Acid Absorption To Regulate Systemic Lipid Metabolism
Bile Acids Selectively Drive Fatty Acid Absorption To Regulate Systemic Lipid Metabolism
Coffee Available
4:30–5:00 PM
Van Horne Foyer
New Non-invasive Measures of MASH/Fibrosis
5:00–6:45 PM
Van Horne B
* Hannele Yki-Järvinen, University of Helsinki
Session Chair
Session Chair
* Quentin M. Anstee, Newcastle University
New Non-invasive Biomarkers for MASH Data from Litmus
New Non-invasive Biomarkers for MASH Data from Litmus
Sami F Qadri, University of Helsinki
Surveillance of the Liver in Type 2 Diabetes: Important but Unfeasible?
Surveillance of the Liver in Type 2 Diabetes: Important but Unfeasible?
Manal F. Abdelmalek, Mayo Clinic
Whole Genome Methylation Cell-Free DNA Signature and Methylome-Wide Association Study For Non-Invasive Diagnosis of At-Risk MASH
Whole Genome Methylation Cell-Free DNA Signature and Methylome-Wide Association Study For Non-Invasive Diagnosis of At-Risk MASH
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Van Horne B
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Poster Session 3
7:30–10:00 PM
Van Horne C
Thursday, February 27, 2025
Departure
12:00–11:59 PM
Subscribe for Updates